Established and emerging biomarkers in systemic sclerosis: from antibody specificities to molecular signatures and cytokine profiling

Systemic sclerosis (SSc) is a systemic autoimmune rheumatic disease characterized by immune dysregulation, microvascular injury and fibrosis of the vessels, skin and internal organs. Biomarkers are critical to establish prognosis and to guide early intervention. This narrative review evaluates the diagnostic utility, pathogenic roles and level of clinical evidence for autoantibodies, soluble proteins, cytokines and genetic loci in SSc, and groups non-antibody markers by the process they mainly reflect. Several studies identified associations between SSc phenotypes and anticentromere, anti-topoisomerase I and anti-RNA polymerase III antibodies, which remain the best-established serological biomarkers, whereas anti-Ro52, anti-Th/To, anti-U3 RNP, anti-BICD2 and functional antibodies define additional organ-specific and vascular phenotypes. Interleukin (IL)-6, IL-1, IL-17, type I interferon signatures and chemokines reflect immune activation; adhesion molecules, soluble endoglin, endostatin and fractalkine reflect endothelial dysfunction; and transforming growth factor-β, IL-4, IL-13, IL-11 and collagen turnover markers reflect fibrogenesis. Krebs von den Lungen-6 (KL-6), the most widely tested marker of SSc-associated interstitial lung disease, and surfactant protein D mainly reflect alveolar epithelial injury. Genetic variants in IRF5, STAT4, TNFAIP3, BANK1 and other loci inform susceptibility rather than diagnosis. These groups are interconnected - inflammation injures the endothelium, vascular injury sustains inflammation and fibroblast activation, and mediators such as IL-6 and transforming growth factor-β act across all three. Apart from classification autoantibodies, most candidates still require external validation before organ-focused biomarker panels can support earlier diagnosis and tailored treatment.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-16
DOI
https://doi.org/10.3389/fimmu.2026.2003839
Primary Topic
Systemic Sclerosis and Related Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Established and emerging biomarkers in systemic sclerosis: from antibody specificities to molecular signatures and cytokine profiling

Г. А. Тогизбаев, Lina N. Zaripova, Rustem Tuleutayev, Diana Makimova et al.
Frontiers in Immunology
Systemic Sclerosis and Related Diseases
article

Established and emerging biomarkers in systemic sclerosis: from antibody specificities to molecular signatures and cytokine profiling

Г. А. Тогизбаев, Lina N. Zaripova, Rustem Tuleutayev, Diana Makimova, Anel Zhumabek, Nuraiym Orynbaikyzy
article en

Abstract

Systemic sclerosis (SSc) is a systemic autoimmune rheumatic disease characterized by immune dysregulation, microvascular injury and fibrosis of the vessels, skin and internal organs. Biomarkers are critical to establish prognosis and to guide early intervention. This narrative review evaluates the diagnostic utility, pathogenic roles and level of clinical evidence for autoantibodies, soluble proteins, cytokines and genetic loci in SSc, and groups non-antibody markers by the process they mainly reflect. Several studies identified associations between SSc phenotypes and anticentromere, anti-topoisomerase I and anti-RNA polymerase III antibodies, which remain the best-established serological biomarkers, whereas anti-Ro52, anti-Th/To, anti-U3 RNP, anti-BICD2 and functional antibodies define additional organ-specific and vascular phenotypes. Interleukin (IL)-6, IL-1, IL-17, type I interferon signatures and chemokines reflect immune activation; adhesion molecules, soluble endoglin, endostatin and fractalkine reflect endothelial dysfunction; and transforming growth factor-β, IL-4, IL-13, IL-11 and collagen turnover markers reflect fibrogenesis. Krebs von den Lungen-6 (KL-6), the most widely tested marker of SSc-associated interstitial lung disease, and surfactant protein D mainly reflect alveolar epithelial injury. Genetic variants in IRF5, STAT4, TNFAIP3, BANK1 and other loci inform susceptibility rather than diagnosis. These groups are interconnected - inflammation injures the endothelium, vascular injury sustains inflammation and fibroblast activation, and mediators such as IL-6 and transforming growth factor-β act across all three. Apart from classification autoantibodies, most candidates still require external validation before organ-focused biomarker panels can support earlier diagnosis and tailored treatment.

Frontiers in ImmunologyVol. 17
Kazakh Institute of Oncology and Radiology (KZ), Astana Medical University (KZ), JSC "Research Institute of Cardiology and Internal Diseases" (KZ)
Systemic Sclerosis and Related Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon